1. Methylation of suppressor of cytokine signalling 1 gene promoter is associated with acute‐on‐chronic hepatitis B liver failure
   J.‐J. Zhang et al, 2015, Journal of Viral Hepatitis CrossRef
2. Upregulation of miR-137 reverses sorafenib resistance and cancer-initiating cell phenotypes by degrading ANT2 in hepatocellular carcinoma
   Ai-Qing Lu et al, 2017, Oncology Reports CrossRef
3. Suppression of ANT2 by miR-137 Inhibits Prostate Tumorigenesis
   Heyuan Zhang et al, 2021, Frontiers in Genetics CrossRef
4. Adenine nucleotide translocase 1 overexpression protects cardiomyocytes against hypoxia via increased ERK1/2 and AKT activation
   Julia Winter et al, 2016, Cellular Signalling CrossRef
5. Identification of new highly selective inhibitors of the human ADP/ATP carriers by molecular docking and in vitro transport assays
   Simona Todisco et al, 2016, Biochemical Pharmacology CrossRef
6. Non-coding RNAs: Emerging Regulators of Sorafenib Resistance in Hepatocellular Carcinoma
   Yongting Lai et al, 2019, Frontiers in Oncology CrossRef
7. Targeting Adenine Nucleotide Translocase-2 (ANT2) to Overcome Resistance to Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor in Non–Small Cell Lung Cancer
   Ji-Young Jang et al, 2016, Molecular Cancer Therapeutics CrossRef
8. Differential Expression of ADP/ATP Carriers as a Biomarker of Metabolic Remodeling and Survival in Kidney Cancers
   Lucia Trisolini et al, 2020, Biomolecules CrossRef
9. The role of microRNA-21 in the onset and progression of cancer
   Ashutosh Singh et al, 2021, Future Medicinal Chemistry CrossRef
10. ANT2 shRNA downregulates miR-19a and miR-96 through the PI3K/Akt pathway and suppresses tumor growth in hepatocellular carcinoma cells
    Seung Hyun Baik et al, 2016, Experimental & Molecular Medicine CrossRef
11. SOCS1 methylation level is associated with prognosis in patients with acute-on-chronic hepatitis B liver failure
    Feng Li et al, 2023, Clinical Epigenetics CrossRef